NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Movement Disorders
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Enrollment
- 20
- Locations
- 1
- Status
- Completed
- Last Updated
- 18 years ago
Overview
Brief Summary
Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Patients with the disease experience, rigid muscles, stooped posture, and a shuffling-type walk (gait).
In this study researchers plan to evaluate the effectiveness of the drug eliprodil for the treatment of Parkinson's Disease. Eliprodil works by blocking special receptors (NMDA) that are associated with the symptoms of Parkinson's Disease.
Detailed Description
The objectives of this study are to evaluate the acute effects of the NR2B subtype-selective NMDA antagonist eliprodil on levodopa-associated motor response complications in patients with advanced Parkinson's Disease (PD).
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified